Cargando…

Estimation of Health-Related Utilities for (177)Lu-DOTATATE in GEP-NET Patients Using Utilities Mapped from EORTC QLQ-C30 to EQ-5D-3L and QLU-C10D Utilities

BACKGROUND: Gastroenteropancreatic neuroendocrine tumours (GEP-NET) are a rare, life-threatening type of cancer. The survival benefit of (177)Lu-DOTATATE has been demonstrated in GEP-NET patients. Health technology assessment bodies require data on health-related utility impacts of treatment. A canc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Soare, Ioana-Alexandra, Leeuwenkamp, Oscar, Longworth, Louise
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611167/ https://www.ncbi.nlm.nih.gov/pubmed/34260017 http://dx.doi.org/10.1007/s41669-021-00280-9

Ejemplares similares

The EORTC QLU-C10D: The Canadian Valuation Study and Algorithm to Derive Cancer-Specific Utilities From the EORTC QLQ-C30
por: McTaggart-Cowan, Helen, et al.
Publicado: (2019)

German value sets for the EORTC QLU-C10D, a cancer-specific utility instrument based on the EORTC QLQ-C30
por: Kemmler, Georg, et al.
Publicado: (2019)

Dutch utility weights for the EORTC cancer-specific utility instrument: the Dutch EORTC QLU-C10D
por: Jansen, Femke, et al.
Publicado: (2021)

Australian Utility Weights for the EORTC QLU-C10D, a Multi-Attribute Utility Instrument Derived from the Cancer-Specific Quality of Life Questionnaire, EORTC QLQ-C30
por: King, Madeleine T., et al.
Publicado: (2017)

Mapping the EORTC QLQ-C30 and QLQ-H&N35 to the EQ-5D for head and neck cancer: Can disease-specific utilities be obtained?
por: Beck, Ann-Jean C. C., et al.
Publicado: (2019)

Comparison of EQ-5D-3L with QLU-C10D in Metastatic Melanoma Using Cost-Utility Analysis
por: Kim, Hansoo, et al.
Publicado: (2021)

Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma
por: Proskorovsky, Irina, et al.
Publicado: (2014)

The validation of published utility mapping algorithms: an example of EORTC QLQ-C30 and EQ-5D in non-small cell lung cancer
por: Gregory, Joanne, et al.
Publicado: (2020)

The EORTC QLU-C10D discrete choice experiment for cancer patients: a first step towards patient utility weights
por: Gamper, Eva-Maria, et al.
Publicado: (2022)

EORTC QLU-C10D value sets for Austria, Italy, and Poland
por: Gamper, E. M., et al.
Publicado: (2020)

Mapping EORTC QLQ-C30 onto EQ-5D for the assessment of cancer patients
por: Kim, Seon Ha, et al.
Publicado: (2012)

Mapping the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer
por: Gray, Laura A., et al.
Publicado: (2021)

Correction to: Mapping the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer
por: Gray, Laura A., et al.
Publicado: (2022)

Reference values of EORTC QLQ-C30, EORTC QLQ-BR23, and EQ-5D-5L for women with non-metastatic breast cancer at diagnosis and 2 years after
por: Miret, Carme, et al.
Publicado: (2023)

Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma
por: Arnold, David T, et al.
Publicado: (2015)

Mapping EORTC-QLQ-C30 onto EQ-5D-5L Index in Indonesian Cancer Patients
por: Perwitasari, Dyah Aryani, et al.
Publicado: (2023)

Lutetium Lu-177 Dotatate Flare Reaction
por: Salner, Andrew L., et al.
Publicado: (2020)

Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with (177)Lu-DOTATATE
por: Strosberg, Jonathan R., et al.
Publicado: (2021)

Interpreting Within-Patient Changes on the EORTC QLQ-C30 and EORTC QLQ-LC13
por: Coon, Cheryl D., et al.
Publicado: (2022)

Use of [(177)Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study
por: Glover, Matthew, et al.
Publicado: (2021)

Mapping EORTC QLQ-C30 and FACT-G onto EQ-5D-5L index for patients with cancer
por: Hagiwara, Yasuhiro, et al.
Publicado: (2020)

Mapping the EORTC QLQ-C30 onto the EQ-5D-5L index for patients with paroxysmal nocturnal hemoglobinuria in France
por: Wojciechowski, Piotr, et al.
Publicado: (2023)

Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients
por: Khan, Iftekhar, et al.
Publicado: (2016)

Lutetium oxodotreotide ((177)Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland
por: Smith-Palmer, J., et al.
Publicado: (2021)

(90)Y/(177)Lu-DOTATATE therapy: survival of the fittest?
por: Brans, Boudewijn, et al.
Publicado: (2011)

Concomitant (177)Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
por: Yadav, Madhav Prasad, et al.
Publicado: (2019)

(177)Lu-DOTATATE therapy in metastatic/inoperable pheochromocytoma-paraganglioma
por: Kumar Jaiswal, Sanjeet, et al.
Publicado: (2020)

Tissue dose estimation after extravasation of (177)Lu-DOTATATE
por: Tylski, Perrine, et al.
Publicado: (2021)

Efficacy of (177)Lu-Dotatate Therapy in the Treatment of Recurrent Meningioma
por: Zahid, Anza, et al.
Publicado: (2021)

Psychometric properties of the EORTC QLQ-C30 in Uganda
por: Naamala, Allen, et al.
Publicado: (2021)

Assessing measurement invariance in the EORTC QLQ-C30
por: van Roij, Janneke, et al.
Publicado: (2021)

[(177)Lu]Lu-DOTA-TATE versus standard of care in adult patients with gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): a cost-consequence analysis from an Italian hospital perspective
por: Spada, Francesca, et al.
Publicado: (2021)

Practical kidney dosimetry in peptide receptor radionuclide therapy using [(177)Lu]Lu-DOTATOC and [(177)Lu]Lu-DOTATATE with focus on uncertainty estimates
por: Staanum, Peter Frøhlich, et al.
Publicado: (2021)

Estimation of an EORTC QLU-C10 Value Set for Spain Using a Discrete Choice Experiment
por: Finch, Aureliano Paolo, et al.
Publicado: (2021)

Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with (177)Lu-DOTATATE
por: Vyakaranam, Achyut Ram, et al.
Publicado: (2019)

Repurposed Effect of (177)Lu-DOTATATE in the Treatment of Mantle Cell Lymphoma
por: Elajami, Mohamad K., et al.
Publicado: (2022)

A Comparison of 2D and 3D Kidney Absorbed Dose Measures in Patients Receiving (177)Lu-DOTATATE
por: Willowson, Kathy P, et al.
Publicado: (2018)

Reliability and Validity of the Arabic Version of the EORTC QLQ-C30 and QLQ-BR23 Questionnaires
por: Jassim, Ghufran, et al.
Publicado: (2020)

Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model
por: Franken, Mira D., et al.
Publicado: (2020)

Clinical efficacy of (177)Lu-DOTATATE peptide receptor radionuclide therapy in thyroglobulin-elevated negative iodine scintigraphy: A “not-so-promising” result compared to GEP-NETs
por: Basu, Sandip, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fc7aub228b3rsd4u4o4jrv4ua1